Skip to main
ANGO
ANGO logo

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc. is experiencing robust growth, particularly through its Auryon product line, which is expanding its customer base in both outpatient business locations and hospitals, thereby enhancing average selling prices (ASP). The company is also on track to improve its gross margin, which is currently at 52.5%, through ongoing manufacturing initiatives expected to be completed by January 2026, alongside a favorable revenue mix skewed towards higher Med-Tech revenues. Additionally, management is optimistic about sustained growth driven by acquiring new customers, increasing utilization in existing accounts, and effective pricing strategies in place.

Bears say

AngioDynamics faces significant challenges, including anticipated tariff headwinds of $4M-$6M, which could adversely affect its profitability. Additionally, the company's management has expressed concerns regarding increased raw material prices, potentially impacting inventory for the second half of 2026. Furthermore, while recent capital sales have boosted performance, the reliance on this segment raises questions about the sustainability of future disposable demand.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.